RootBridge Capital
Zürich, Zurich, Switzerland, Europe
Overview
RootBridge Capital manages an alternative investment fund that focuses on opportunities linked to India’s economic formalisation and expanding consumer base. The firm invests in both private and public markets, with a particular emphasis on PIPE deals in publicly listed, high‑growth Indian companies. Its strategy targets businesses benefiting from urbanisation, rising middle‑class consumption, and structural transformation across the Indian economy. RootBridge Capital deploys capital across sectors including food and beverage, retail, consumer goods, fintech, AI and deeptech, industrials, and mobility. The fund is intended for qualified and professional investors and aims to capture differentiated returns from India’s evolving consumer, digital, and industrial landscape.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Investment portfolio
- Omni
Participated · Equity · Jun 2026
Omni develops a range of plant-based, vet-formulated dog foods, treats, supplements, dental sticks, shampoos and calming products using novel proteins from yeast, algae and pulses. The company sells dry foods and wet-style meals, training treats, and a portfolio of supplements addressing skin, breath, gut health and weight management. Omni is commercial and growing quickly—founders Guy Sandelowsky and Shiv Sivakumar say annualised sales rose from about £1M to close to £13M and the brand has helped more than 300,000 dogs, with a 130% sales lift and 20,000 new customers after its Dragons’ Den appearance. It is developing LeanPaws, an Ozempic-style weight-loss supplement for dogs; a placebo-controlled trial reported 77% of overweight dogs taking LeanPaws lost some weight, 63% reduced body fat composition, and 42% showed fewer begging behaviors with virtually no side effects. Omni highlights the lower carbon footprint of its recipes—about 73% fewer emissions than standard meat-based dog food—and cites avoided customer CO2e contributions over time. The company plans to use new funding to scale UK retail presence, enter the US market, continue clinical research, and expand the team.
Team
No current team members are available.